202 related articles for article (PubMed ID: 35903534)
1. TERT Promoter Mutations and Telomerase in Melanoma.
Guo Y; Chen Y; Zhang L; Ma L; Jiang K; Yao G; Zhu L
J Oncol; 2022; 2022():6300329. PubMed ID: 35903534
[TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.
Roh MR; Park KH; Chung KY; Shin SJ; Rha SY; Tsao H
Am J Cancer Res; 2017; 7(1):134-138. PubMed ID: 28123854
[TBL] [Abstract][Full Text] [Related]
3.
Hafezi F; Jaxel L; Lemaire M; Turner JD; Perez-Bercoff D
Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944589
[No Abstract] [Full Text] [Related]
4. TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic Apoptosis.
Wang Y; Chen Y; Li C; Xiao Z; Yuan H; Zhang Y; Pang D; Tang X; Li M; Ouyang H
Biology (Basel); 2022 Jan; 11(1):. PubMed ID: 35053139
[TBL] [Abstract][Full Text] [Related]
5. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
[TBL] [Abstract][Full Text] [Related]
6. Classifying Melanoma by TERT Promoter Mutational Status.
Shaughnessy M; Njauw CN; Artomov M; Tsao H
J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations in telomere biology.
Heidenreich B; Kumar R
Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
[TBL] [Abstract][Full Text] [Related]
8. TERT Promoter Mutations in Papillary Thyroid Microcarcinomas.
de Biase D; Gandolfi G; Ragazzi M; Eszlinger M; Sancisi V; Gugnoni M; Visani M; Pession A; Casadei G; Durante C; Costante G; Bruno R; Torlontano M; Paschke R; Filetti S; Piana S; Frasoldati A; Tallini G; Ciarrocchi A
Thyroid; 2015 Sep; 25(9):1013-9. PubMed ID: 26148423
[TBL] [Abstract][Full Text] [Related]
9. Frequency of TERT promoter mutations in primary tumors of the liver.
Quaas A; Oldopp T; Tharun L; Klingenfeld C; Krech T; Sauter G; Grob TJ
Virchows Arch; 2014 Dec; 465(6):673-7. PubMed ID: 25267585
[TBL] [Abstract][Full Text] [Related]
10. Occurrence, functionality and abundance of the TERT promoter mutations.
Rachakonda S; Hoheisel JD; Kumar R
Int J Cancer; 2021 Dec; 149(11):1852-1862. PubMed ID: 34313327
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
[TBL] [Abstract][Full Text] [Related]
12. Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma.
Lindner S; Bachmann HS; Odersky A; Schaefers S; Klein-Hitpass L; Hero B; Fischer M; Eggert A; Schramm A; Schulte JH
Biomed Rep; 2015 Jul; 3(4):443-446. PubMed ID: 26171145
[TBL] [Abstract][Full Text] [Related]
13. Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients.
Manrique-Silva E; David ME; Maider AM; García-Casado Z; Moro R; Requena C; Través V; Virós A; Kumar R; Nagore E
Pigment Cell Melanoma Res; 2024 May; 37(3):343-351. PubMed ID: 38153178
[TBL] [Abstract][Full Text] [Related]
14. E4F1 and ZNF148 are transcriptional activators of the -57A > C and wild-type
Chua BH; Zaal Anuar N; Ferry L; Domrane C; Wittek A; Mukundan VT; Jha S; Butter F; Tenen DG; Defossez PA; Kappei D
Genome Res; 2023 Nov; 33(11):1893-905. PubMed ID: 37918959
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
Griewank KG; Murali R; Schilling B; Schimming T; Möller I; Moll I; Schwamborn M; Sucker A; Zimmer L; Schadendorf D; Hillen U
PLoS One; 2013; 8(11):e80354. PubMed ID: 24260374
[TBL] [Abstract][Full Text] [Related]
16. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs).
Campanella NC; Celestino R; Pestana A; Scapulatempo-Neto C; de Oliveira AT; Brito MJ; Gouveia A; Lopes JM; Guimarães DP; Soares P; Reis RM
Eur J Hum Genet; 2015 Jun; 23(6):877-9. PubMed ID: 25248398
[TBL] [Abstract][Full Text] [Related]
17. TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients.
Del Bianco P; Stagni C; Giunco S; Fabozzi A; Elefanti L; Pellegrini S; Vecchiato A; Pigozzo J; Zamuner C; De Rossi A; De Nicolo A; Menin C
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290374
[TBL] [Abstract][Full Text] [Related]
18. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
[TBL] [Abstract][Full Text] [Related]
20. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
